Montreal Cognitive Assessment and Mini-Mental State Examination reliable change indices in healthy older adults
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
27352935
DOI
10.1002/gps.4539
Knihovny.cz E-resources
- Keywords
- aging, cognition, reliability and validity,
- MeSH
- Analysis of Variance MeSH
- Geriatric Assessment methods MeSH
- Cognitive Dysfunction diagnosis MeSH
- Brief Psychiatric Rating Scale MeSH
- Middle Aged MeSH
- Humans MeSH
- Neuropsychological Tests * MeSH
- Disease Progression MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Mental Status and Dementia Tests * MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Research Support, N.I.H., Extramural MeSH
OBJECTIVE: Cognitive tests are used repeatedly to assess the treatment response or progression of cognitive disorders. The Montreal Cognitive Assessment (MoCA) is a valid screening test for mild cognitive impairment. The aim of our study was to establish 90% reliable change indices (RCI) for the MoCA together with the Mini-Mental State Examination (MMSE) in cognitively healthy older adults. METHOD: We analyzed 197 cognitively healthy and functional independent volunteers aged 60-94 years, who met strict inclusion criteria for four consecutive years. The RCI methods by Chelune and Hsu were used. RESULTS: For 1, 2, and 3 years, the 90% RCI for MoCA using Chelune's formula were -4 ≤, ≥4; -4 ≤, ≥4 and -5 ≤, ≥4 points, respectively, and -3 ≤, ≥3 for the MMSE each year. Ninety percent RCI for MoCA using Hsu's formula ranged from -6 to 0, respectively, and +3 to +8 dependent on the baseline MoCA. CONCLUSION: Our study demonstrated RCI for the MoCA and MMSE in a 3-year time period that can be used for the estimation of cognitive decline or improvement in clinical settings. Copyright © 2016 John Wiley & Sons, Ltd.
References provided by Crossref.org
Four questions to predict cognitive decline in de novo Parkinson's disease